. 2022 Aug 26;14(8):658–679. doi: 10.4252/wjsc.v14.i8.658

Table 2.

Characteristics of mesenchymal stem cells

Ref.	Mesenchymal stem cells					Transplantation
Ref.	Donor	Source	Surface marker	Passage	Modification	Cell dose	Route	Volume (µL)
Lee et al[9]	Human	Tonsil	Negative: CD14, CD34, CD45, HLA-DR, CD40, CD80, CD86 CD11b, CD21, CD23, CD35 and CD54	P3-5	MMP3-knockdown	1 × 10⁶	IV	NR
Lee et al[9]	Human	Tonsil	Positive: CD73, CD95 and CD105	P3-5	MMP3-knockdown	1 × 10⁶	IV	NR
Huang et al[10]	Human	UCB	Negative: CD34 and CD45	P4	NA	5 × 10⁶; 1 × 10⁶	IV; IB	NR
Huang et al[10]	Human	UCB	Positive: CD90, CD105 and CD75	P4	NA	5 × 10⁶; 1 × 10⁶	IV; IB	NR
Yin et al[8]	Human	UCB	NR	NR	GFP; EGF; FGF2; PDGFB	5 × 10⁵	IB	10
Choi et al[11]	Human	Tonsil	Negative: CD14, CD34, CD45, HLA-DR, CD40, CD80, CD86 CD11b, CD21, CD23, CD35 and CD54	P3-5	NA	2 × 10⁶	IV	200
Choi et al[11]	Human	Tonsil	Positive: CD73, CD95 and CD105	P3-5	NA	2 × 10⁶	IV	200
Trento et al[12]	Mice (C57BL/6 CD45.2 orNos2^-/-)	BM	Negative: CD45	Max P8	Nos2^-/-	2 × 10⁵	IV	NR
Trento et al[12]	Mice (C57BL/6 CD45.2 orNos2^-/-)	BM	Positive: PDGFRα and Sca-1	Max P8	Nos2^-/-	2 × 10⁵	IV	NR
Abbuehl et al[13]	Mice (FVB Insulin-GFP)	BM	Negative: CD105	NR	NA	1 × 10⁴	IB	3
Abbuehl et al[13]	Mice (FVB Insulin-GFP)	BM	Positive: CD73 and Sca1	NR	NA	1 × 10⁴	IB	3
Kim et al[14]	Mice (C57BL/6J-Ly 5.2 BL6)	BM	Negative: CD45	Min P2	NA	2 × 10⁵	NR	NR
Futrega et al[15]	Human	BM	Negative: CD45, CD34 and HLA-DR	P3	NA	5 × 10⁵	IV; IB	100; 10
Futrega et al[15]	Human	BM	Positive: CD44, CD90, CD73, CD105 and CD146	P3	NA	5 × 10⁵	IV; IB	100; 10
van der Garde et al[16]	Human	FL	Negative: CD34	NR	NA	1 × 10⁶	IV	NR
Fernández-García et al[17]	Mice (B6D2F1, H2b/d, CD45.2)	AT	Negative: CD34, CD45.1 and CD80Low: Sca-1	P5-8	NA	2 × 10⁵; 4 × 10⁵; 6-10 × 10⁵	IV	NR
Fernández-García et al[17]	Mice (B6D2F1, H2b/d, CD45.2)	AT	Positive: CD29, CD44, CD73, CD90.2, CD105, CD106, CD144, and CD166	P5-8	NA	2 × 10⁵; 4 × 10⁵; 6-10 × 10⁵	IV	NR
Chen et al[18]	Mice (C57BL/6)	BM	NR	P3-8	CXCR4	5 × 10⁵	IV	NR
Chen et al[19]	Human	BM	Negative: CD34 and CD45	NR	SDF1; HOXB4	8 × 10⁵	IV	NR
Chen et al[19]	Human	BM	Positive: CD90 and CD44	NR	SDF1; HOXB4	8 × 10⁵	IV	NR
Wu et al[20]	Human	UCB	Negative: CD14, CD31, CD34, CD45, and HLA-DR	NR	NA	1 × 10⁶	IV	250
Wu et al[20]	Human	UCB	Positive: CD13, CD29, CD44, CD73, CD90, and CD105	NR	NA	1 × 10⁶	IV	250
Lim et al[21]	Human	UCB	Negative: CD14, CD34 and CD45	P4	NA	5 × 10⁶	IV	200
Lim et al[21]	Human	UCB	Positive: CD73 and CD105	P4	NA	5 × 10⁶	IV	200
Lee et al[22]	Human	UCB; AT; BM	Negative: CD14, CD34, and CD45	NR	NA	1 × 10⁶	IV	150-200
Lee et al[22]	Human	UCB; AT; BM	Positive: CD73, CD90, and CD105	NR	NA	1 × 10⁶	IV	150-200
Kornblit et al[23]	Dog (beagle)	BM	NR	P1	NA	4.8-10 × 10⁸/kg	IV	50 mL
Fortin et al[24]	Mice	BM	Negative: CD45 and CD31	NR	solG-CSFR	1.5 × 10⁷	IP	NR
Fortin et al[24]	Mice	BM	Positive: CD44 and CD90^dim	NR	solG-CSFR	1.5 × 10⁷	IP	NR
Carrancio et al[25]	Human	BM	Positive: CD73, CD90, CD105, CD44, and CD166	P3	NA	5 × 10⁵	IV; IB	200; 20

AT: Adipose tissue; FL: Fetal lung; BM: Bone marrow; UCB: Umbilical cord blood; MMP3: Matrix metallopeptidase 3; GFP: Green fluorescent protein; EGF: Epidermic growth factor; FDF2: Fibroblast growth factor 2; PDGFB: Platelet-derived growth factor subunit B; CXCR4: C-X-C chemokine receptor type 4; SDF-1: Stromal cell-derived factor 1; HOXB4: Homeobox B4; solG-CSFR: Soluble granulocyte colony-stimulating factor decoy receptor; TPO: Thrombopoietin; Nos2^-/^-: Deficient in type 2 nitric oxide; IP: Intraperitoneal; IV: Intravenous; IB: Intrabone; NR: Not reported; NA: Not applied.